OptimizeRx Corp
Close on Oct 19, 2026
- Market cap
- $164.19M
- P/E (TTM)
- 36.4
- Dividend yield
- –
About OptimizeRx
Services-Business Services, NEC, SIC 7389
OptimizeRx Corporation provides digital healthcare technology and marketing solutions for the life sciences sector. The company offers technology platforms that enable pharmaceutical manufacturers and marketing agencies to reach healthcare professionals and patients. Its core solutions include an artificial intelligence-driven Dynamic Audience Activation Platform, patent-protected Micro-Neighborhood Targeting, and audience profiling tools. It also delivers banner messaging through point-of-care networks, real-time pharmacy dispensing alerts, and financial copay messaging integrated directly into electronic health record systems and electronic prescribing platforms.
The company connects more than two million healthcare providers in the United States and millions of patients, serving over one hundred pharmaceutical manufacturer clients. Its workforce operates primarily remotely across the United States and Croatia, supported by technical contractors located in India, Ukraine, Croatia, and the United States. In addition, the firm conducts operations through a subsidiary in Croatia. OptimizeRx maintains its principal executive offices in Waltham, Massachusetts.
Summary of the business section of OptimizeRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OptimizeRx Corp
- Founded
- 2006
- Headquarters
- Waltham, MA
- Address
- 260 Charles Street, Suite 302 02453
- Phone
- (248) 651-6558
- Website
- optimizerx.com
- Employees
- 104, Dec 31, 2025
- Industry
- Services-Business Services, NEC
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- UHY LLP, Sterling Heights, Michigan
Stock & identifiers
- Ticker
- OPRX
- Exchange
- Nasdaq
- Shares outstanding
- 19M, Jul 30, 2026
- Public float
- $240.86M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-3 reverse, Aug 7, 2018; 1-for-3 reverse, May 14, 2018
- SEC CIK
- 1448431
- CUSIP
- 68401U204
- ISIN
- US68401U2042
- EIN
- 26-1265381
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William J. Febbo | CEO, Director | 600,852 |
| Andrew J. D'Silva | Chief Business Officer | 99,660 |
| Brendan W. Merrell | CHIEF OPERATING OFFICER | 25,187 |
| Edward Stelmakh | Chief Finance & Strat Officer | 121,791 |
| Stephen L. Silvestro | Chief Executive Officer | 262,751 |
| Marion Odence-Ford | Chief Legal & Admin Officer | 90,407 |
| Theresa Greco | Chief Commercial Officer | 71,954 |
| Doug Besch | Chief Product & Tech Officer | 66,876 |
| Mariyamma Varghese Presti | Director | 13,060 |
| Ellen O'Connor Vos | Director | 135,159 |
| Gregory D. Wasson | Director | 91,700 |
| James Paul Lang | Director | 433,837 |
| Patrick D. Spangler | Director | 78,732 |
| Cathy Klema | Director | 56,137 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Stephen Silvestro | $2.72M | $3.85M | $1.53M | $73 | – |
| FY2025 William Febbo | $0 | $0 | $1.53M | $73 | – |
| FY2024 William Febbo | $2.27M | -$305.93K | $991.22K | $29 | – |
| FY2024 William J.Febbo | $2.27M | -$305.93K | $991.22K | $29 | – |
| FY2023 William Febbo | $2.79M | $2.30M | $950.04K | $85 | – |
| FY2023 William J.Febbo | $2.79M | $2.30M | $950.04K | $85 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 104 full-time employees and 1 part-time employee in the U.S, as well as 28 full-time employees in Croatia.”
Corporate history
Events identified from SEC filings